Logo image of EPRX

EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Fundamental Analysis

USA - NASDAQ:EPRX - CA29842P1053 - Common Stock

5.75 USD
-0.13 (-2.21%)
Last: 10/21/2025, 10:01:04 AM
Fundamental Rating

3

EPRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. EPRX has a great financial health rating, but its profitability evaluates not so good. EPRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year EPRX has reported negative net income.
EPRX had a negative operating cash flow in the past year.
EPRX had negative earnings in each of the past 5 years.
In the past 5 years EPRX always reported negative operating cash flow.
EPRX Yearly Net Income VS EBIT VS OCF VS FCFEPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of EPRX (-122.72%) is worse than 80.15% of its industry peers.
With a Return On Equity value of -128.38%, EPRX perfoms like the industry average, outperforming 40.07% of the companies in the same industry.
Industry RankSector Rank
ROA -122.72%
ROE -128.38%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX Yearly ROA, ROE, ROICEPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EPRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX Yearly Profit, Operating, Gross MarginsEPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

8

2. Health

2.1 Basic Checks

The number of shares outstanding for EPRX has been increased compared to 1 year ago.
Compared to 5 years ago, EPRX has more shares outstanding
EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPRX Yearly Shares OutstandingEPRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX Yearly Total Debt VS Total AssetsEPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

EPRX has an Altman-Z score of 159.94. This indicates that EPRX is financially healthy and has little risk of bankruptcy at the moment.
EPRX has a better Altman-Z score (159.94) than 99.06% of its industry peers.
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 159.94
ROIC/WACCN/A
WACCN/A
EPRX Yearly LT Debt VS Equity VS FCFEPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

EPRX has a Current Ratio of 8.72. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.72, EPRX is doing good in the industry, outperforming 76.59% of the companies in the same industry.
EPRX has a Quick Ratio of 8.72. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.72, EPRX is in the better half of the industry, outperforming 76.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.72
Quick Ratio 8.72
EPRX Yearly Current Assets VS Current LiabilitesEPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. Growth

3.1 Past

The earnings per share for EPRX have decreased by -2.36% in the last year.
EPS 1Y (TTM)-2.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, EPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.90% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.59%
EPS Next 2Y3.54%
EPS Next 3Y17.91%
EPS Next 5Y12.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX Yearly Revenue VS EstimatesEPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
EPRX Yearly EPS VS EstimatesEPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

0

4. Valuation

4.1 Price/Earnings Ratio

EPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX Price Earnings VS Forward Price EarningsEPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX Per share dataEPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as EPRX's earnings are expected to grow with 17.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.54%
EPS Next 3Y17.91%

0

5. Dividend

5.1 Amount

No dividends for EPRX!.
Industry RankSector Rank
Dividend Yield N/A

EUPRAXIA PHARMACEUTICALS INC

NASDAQ:EPRX (10/21/2025, 10:01:04 AM)

5.75

-0.13 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-05 2025-11-05
Inst Owners5.35%
Inst Owner ChangeN/A
Ins Owners19.13%
Ins Owner ChangeN/A
Market Cap290.95M
Analysts84.44
Price Target8.06 (40.17%)
Short Float %0.64%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.72%
Min EPS beat(2)-41.57%
Max EPS beat(2)-23.87%
EPS beat(4)1
Avg EPS beat(4)-33.12%
Min EPS beat(4)-80.04%
Max EPS beat(4)12.99%
EPS beat(8)4
Avg EPS beat(8)-18.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.58%
PT rev (3m)-2.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.86%
EPS NY rev (1m)-3.94%
EPS NY rev (3m)-12.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.9
P/tB 12.9
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0
BVpS0.45
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.72%
ROE -128.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 252.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.72
Quick Ratio 8.72
Altman-Z 159.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.51%
EPS Next Y-6.59%
EPS Next 2Y3.54%
EPS Next 3Y17.91%
EPS Next 5Y12.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.35%
OCF growth 3YN/A
OCF growth 5YN/A